NASDAQ:ALVO - Nasdaq - LU2458332611 - Common Stock - Currency: USD
12.28
+0.58 (+4.96%)
The current stock price of ALVO is 12.28 USD. In the past month the price decreased by -6.4%. In the past year, price decreased by -23.39%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Alvotech operates as a global biopharmaceutical company, which engages in developing and manufacturing biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
ALVOTECH SA
9, Rue De Bitbourg
Luxembourg LU
Employees: 999
Company Website: https://www.alvotech.com/
Investor Relations: http://investors.alvotech.com/
Phone: 35244224500
The current stock price of ALVO is 12.28 USD. The price increased by 4.96% in the last trading session.
The exchange symbol of ALVOTECH SA is ALVO and it is listed on the Nasdaq exchange.
ALVO stock is listed on the Nasdaq exchange.
10 analysts have analysed ALVO and the average price target is 19.38 USD. This implies a price increase of 57.82% is expected in the next year compared to the current price of 12.28. Check the ALVOTECH SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ALVOTECH SA (ALVO) has a market capitalization of 3.70B USD. This makes ALVO a Mid Cap stock.
ALVOTECH SA (ALVO) currently has 999 employees.
ALVOTECH SA (ALVO) has a support level at 11.98 and a resistance level at 12.5. Check the full technical report for a detailed analysis of ALVO support and resistance levels.
The Revenue of ALVOTECH SA (ALVO) is expected to grow by 306.52% in the next year. Check the estimates tab for more information on the ALVO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALVO does not pay a dividend.
ALVOTECH SA (ALVO) will report earnings on 2025-02-26, after the market close.
ALVOTECH SA (ALVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.85).
The outstanding short interest for ALVOTECH SA (ALVO) is 0.38% of its float. Check the ownership tab for more information on the ALVO short interest.
ChartMill assigns a technical rating of 1 / 10 to ALVO. When comparing the yearly performance of all stocks, ALVO is a bad performer in the overall market: 77.55% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to ALVO. ALVO may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ALVO reported a non-GAAP Earnings per Share(EPS) of -1.85. The EPS increased by 29.74% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -35.8% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 82% to ALVO. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 70.41% and a revenue growth 306.52% for ALVO